Experimental cocktail aims to shrink tough tumors
NCT ID NCT06760481
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a combination of two immune-boosting drugs (tiragolumab and atezolizumab) plus a special type of radiation (RadScopal) in 7 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and side effects, while also looking for signs that the tumors shrink. Because it is a very small, first-in-human study, the results will only show whether the approach is safe enough to test further.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tiragolumab, Atezolizumab, and Radiation Therapy
- What this could lead to
- If this combination proves safe and effective, it could offer a new treatment option for people with advanced solid tumors who have run out of standard therapies.
- What could go wrong
- This is a very early, small Phase I trial with only 7 participants, so results may not apply broadly. The main goal is safety, not yet proof of benefit, and side effects from the drug combination or radiation could be significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The University of Texas M. D. Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug OB318 enters human testing for Hard-to-Treat cancers
- Tracing a cancer Drug's journey through the body
- Experimental mitochondrial vaccine takes on advanced cancers
- New hope for advanced cancer? early trial of BC2027 begins
- New pill takes on Hard-to-Treat cancers in first human trial
- New cancer drug BR115 enters first human tests